Unresectable Colon Cancer with Charles Fuchs, MD and Tanios Bekaii-Saab, MD: Case 2

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.

In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.